PL2059503T3 - Pochodne aminopirazolu, sposób ich wytwarzania oraz kompozycja do zapobiegania lub leczenia chorób niedokrwiennych zawierająca takie pochodne - Google Patents
Pochodne aminopirazolu, sposób ich wytwarzania oraz kompozycja do zapobiegania lub leczenia chorób niedokrwiennych zawierająca takie pochodneInfo
- Publication number
- PL2059503T3 PL2059503T3 PL07833620T PL07833620T PL2059503T3 PL 2059503 T3 PL2059503 T3 PL 2059503T3 PL 07833620 T PL07833620 T PL 07833620T PL 07833620 T PL07833620 T PL 07833620T PL 2059503 T3 PL2059503 T3 PL 2059503T3
- Authority
- PL
- Poland
- Prior art keywords
- preventing
- preparation
- composition
- same
- ischemic diseases
- Prior art date
Links
- JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical class NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 title 1
- 208000023589 ischemic disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020060105183A KR100832747B1 (ko) | 2006-10-27 | 2006-10-27 | 아미노피라졸 유도체, 이의 제조 방법 및 이를 함유하는허혈성 질환의 예방 또는 치료용 조성물 |
| EP07833620.3A EP2059503B1 (en) | 2006-10-27 | 2007-10-26 | Aminopyrazole derivatives, process for the preparation thereof, and composition for preventing or treating ischemic diseases containing the same |
| PCT/KR2007/005311 WO2008051047A1 (en) | 2006-10-27 | 2007-10-26 | Aminopyrazole derivatives, process for the preparation thereof, and composition for preventing or treating ischemic diseases containing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2059503T3 true PL2059503T3 (pl) | 2016-01-29 |
Family
ID=39324788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL07833620T PL2059503T3 (pl) | 2006-10-27 | 2007-10-26 | Pochodne aminopirazolu, sposób ich wytwarzania oraz kompozycja do zapobiegania lub leczenia chorób niedokrwiennych zawierająca takie pochodne |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7939550B2 (pl) |
| EP (1) | EP2059503B1 (pl) |
| JP (1) | JP5096476B2 (pl) |
| KR (1) | KR100832747B1 (pl) |
| CN (1) | CN101528687B (pl) |
| AU (1) | AU2007309854B2 (pl) |
| CA (1) | CA2666975C (pl) |
| DK (1) | DK2059503T3 (pl) |
| ES (1) | ES2546183T3 (pl) |
| PL (1) | PL2059503T3 (pl) |
| WO (1) | WO2008051047A1 (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2799427T (lt) | 2006-07-05 | 2018-11-26 | Fibrotech Therapeutics Pty Ltd | Terapiniai junginiai |
| AU2008341010B2 (en) | 2007-12-21 | 2013-04-18 | Certa Therapeutics Pty. Ltd. | Halogenated analogues of anti-fibrotic agents |
| EP2947073B1 (en) | 2009-10-22 | 2019-04-03 | Fibrotech Therapeutics Pty Ltd | Fused ring analogues of anti-fibrotic agents |
| CA2955872A1 (en) * | 2014-07-24 | 2016-01-28 | Bayer Pharma Aktiengesellschaft | Glucose transport inhibitors |
| ITUB20159668A1 (it) * | 2015-12-29 | 2017-06-29 | Univ Degli Studi Di Modena E Reggio Emilia | Farmaci antitumorali |
| WO2018144620A1 (en) | 2017-02-03 | 2018-08-09 | Shire Human Genetic Therapies, Inc. | Anti-fibrotic compounds |
| CN110891565A (zh) * | 2017-06-19 | 2020-03-17 | 凯诺斯医药公司 | α-突触核蛋白的调控剂 |
| AU2019214959B2 (en) * | 2018-01-30 | 2023-05-11 | Kainos Medicine Inc. | Salt forms of organic compound |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050209297A1 (en) * | 2000-08-31 | 2005-09-22 | Pfizer Inc | Pyrazole derivatives |
| CA2440211A1 (en) * | 2001-03-09 | 2002-09-19 | Pfizer Products Inc. | Benzimidazole anti-inflammatory compounds |
| EP1651612B9 (en) * | 2003-07-22 | 2012-09-05 | Astex Therapeutics Limited | 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
| US7671072B2 (en) * | 2003-11-26 | 2010-03-02 | Pfizer Inc. | Aminopyrazole derivatives as GSK-3 inhibitors |
| GB0328796D0 (en) * | 2003-12-12 | 2004-01-14 | Biofocus Plc | Compounds which interact with the G-protein coupled receptor family |
| JP2008510726A (ja) * | 2004-08-20 | 2008-04-10 | エントレメッド インコーポレイテッド | プロテイナーゼ活性化受容体アンタゴニストを含む組成物および方法 |
| EP1847531A4 (en) * | 2005-02-09 | 2009-04-22 | Takeda Pharmaceutical | PYRAZOLE DERIVATIVE |
-
2006
- 2006-10-27 KR KR1020060105183A patent/KR100832747B1/ko active IP Right Grant
-
2007
- 2007-10-26 CA CA2666975A patent/CA2666975C/en active Active
- 2007-10-26 AU AU2007309854A patent/AU2007309854B2/en active Active
- 2007-10-26 WO PCT/KR2007/005311 patent/WO2008051047A1/en active Application Filing
- 2007-10-26 DK DK07833620.3T patent/DK2059503T3/en active
- 2007-10-26 PL PL07833620T patent/PL2059503T3/pl unknown
- 2007-10-26 ES ES07833620.3T patent/ES2546183T3/es active Active
- 2007-10-26 JP JP2009534498A patent/JP5096476B2/ja active Active
- 2007-10-26 US US12/447,394 patent/US7939550B2/en active Active
- 2007-10-26 CN CN2007800401170A patent/CN101528687B/zh active Active
- 2007-10-26 EP EP07833620.3A patent/EP2059503B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2059503A1 (en) | 2009-05-20 |
| KR100832747B1 (ko) | 2008-05-27 |
| AU2007309854A1 (en) | 2008-05-02 |
| AU2007309854B2 (en) | 2011-04-28 |
| EP2059503A4 (en) | 2014-07-30 |
| CN101528687B (zh) | 2012-03-14 |
| CA2666975C (en) | 2011-11-15 |
| CA2666975A1 (en) | 2008-05-02 |
| JP5096476B2 (ja) | 2012-12-12 |
| WO2008051047A1 (en) | 2008-05-02 |
| DK2059503T3 (en) | 2015-12-07 |
| US20100063106A1 (en) | 2010-03-11 |
| US7939550B2 (en) | 2011-05-10 |
| EP2059503B1 (en) | 2015-08-26 |
| KR20080037911A (ko) | 2008-05-02 |
| CN101528687A (zh) | 2009-09-09 |
| JP2010507653A (ja) | 2010-03-11 |
| ES2546183T3 (es) | 2015-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL225207A (en) | A derivative of multi-ring carbamoylpyridone, its pharmaceutical composition, its use and its preparation | |
| DK3872058T3 (en) | Process for the preparation of 2,3,3,3 tetrahydrofluoropropene | |
| EP2114904A4 (en) | TRIAZOLE DERIVATIVES WITH ANTIPILY EFFECT, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | |
| IL214183A (en) | Pharma-informatics system and method, preparation for use with it and method for preparation of the preparation | |
| ZA200903160B (en) | Sulfonyl-Phenyl-2H-[1,2,4]Oxodiazol-5-one Derivatives, Processes for their preparation and their use as pharmaceuticals | |
| IL191984A0 (en) | Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents for the treatment of cancer | |
| IL198289A (en) | Processed dihydropyrazolones, processes for their preparation, medicinal preparations containing them and their use in the preparation of medicinal preparations | |
| IL186127A (en) | Subcutaneous preparations for the treatment of depression and methods for their preparation | |
| IL198847A (en) | Process for making 2-imino-thiazolidine-4-on and several such histories | |
| IL193772A0 (en) | 4-oxoquinoline derivatives,methods for the preparation thereof and pharmaceutical compositions containing the same | |
| IL185484A0 (en) | Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents | |
| IL187235A0 (en) | 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament | |
| EP2401263A4 (en) | SUBSTITUTED AZOL DERIVATIVES, PHARMACEUTICAL COMPOSITION WITH THE DERIVATIVES AND METHOD FOR THE TREATMENT OF MORBUS PARKINSON THEREWITH | |
| HUP0500920A2 (en) | Oxadiazole derivatives, process for their preparation and their use | |
| EP2059503A4 (en) | AMINO-PYRAZOL DERIVATIVES, PREPARATION METHOD AND PREPARATION THEREFOR FOR PREVENTION OR TREATMENT OF ISCHEMIC ILLNESSES | |
| IL188861A0 (en) | 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them | |
| TWI315305B (en) | Piperidin-4-yl-amide derivatives,pharmaceutical compositions comprising the same,process for preparing the same and the use thereof | |
| ZA200801896B (en) | Slow-release composition, method for the preparation thereof, and use of the same | |
| HUP0500921A2 (en) | Tetrazole derivatives, process for their preparation and their use | |
| EP1834624A4 (en) | MEDICAL COMPOSITION AND MANUFACTURING METHOD THEREFOR | |
| SI2020410T1 (sl) | Derivati pirido(2,3-d)pirimidina, njihova priprava, njihova terapevtska uporaba | |
| HUP0401522A2 (en) | New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation | |
| EP1781629A4 (en) | NEW BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | |
| SI1783105T1 (sl) | Maltna sestava, postopek za njeno proizvodnjo in njena uporaba | |
| EP2035406A4 (en) | NEW SUBSTITUTED 1H-CHINAZOLIN-2,4-DION DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THEM |